1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Very High Risk Prostate Carcinoma: new trials by email Literature Review of Very High Risk Prostate Carcinoma trials Research Report on Very High Risk Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer [177Lu]Lu-PSMA-617, Ipilimumab - Very High Risk Prostate Carcinoma | Phase 1 / Phase 2 | Terminated | University Hospital, Essen | 1 | 2025-08-25 | 2026-03-13 |
| Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy - Prostate Cancer, Prostate Cancer (Diagnosis) | Phase 1 | Recruiting | Thomas Hope | 45 | 2025-07-08 | 2026-08-28 |
Disease (1) · Prostatic Neoplasms (1)
Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
(225)Ac-PSMA-617 (1) · Blood Specimen Collection (1) · Ipilimumab (1) · Pluvicto (1) · Prostatectomy (1)
Thomas Hope (1) · University Hospital, Essen (1)
Germany (1) · United States (1)